Tamsulosin and cataract surgery complications

Article

According to a report in the Journal of the American Medical Association patients taking tamsulosin for benign prostrate enlargement within 14 days of cataract surgery may have an increased risk of complications.

According to a report in the Journal of the American Medical Association patients taking tamsulosin for benign prostrate enlargement within 14 days of cataract surgery may have an increased risk of complications.

Other similar medications do not increase the risk of these complications — which include lens loss, retinal detachment, and inflammation — according to Dr Chaim M. Bell, from St. Michael's Hospital, Toronto, and colleagues.

The findings hail from a study of 96,128 men, 66 years or older, who underwent cataract surgery in Ontario, Canada from 2002 to 2007. Of these patients, 3550 had taken tamsulosin within 14 days of surgery and 7426 had recent taken other so-called alpha-blocking agents.

Overall, 284 patients experienced an adverse event related to cataract surgery, and 280 of them were matched by age, surgeon, and year of surgery to 1102 patients who did not experience complications.

The report shows that the patients with complications were 2.3 times more likely to have recently taken tamsulosin than the comparison group. By contrast, no significant differences were noted in recent or prior exposure to other alpha-blockers.

The researchers calculate that for every 255 cataract surgery patients who have recently taken tamsulosin, one will develop a serious postop complication.

"Because the combination of cataract surgery and tamsulosin exposure is relatively common, patients should be properly appraised of the risks of drug therapy, and preoperative systems should focus on the identification of tamsulosin use by patients," the authors concluded.

SOURCE: Journal of the American Medical Association.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.